Detalles de la búsqueda
1.
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Ann Oncol
; 35(1): 77-90, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37879444
2.
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
Ann Oncol
; 34(4): 377-388, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36709038
3.
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Ann Oncol
; 33(2): 181-192, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34839016
4.
Foxp3+ Regulatory T Cell Depletion after Nonablative Oligofractionated Irradiation Boosts the Abscopal Effects in Murine Malignant Mesothelioma.
J Immunol
; 205(9): 2519-2531, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32948683
5.
Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial.
Lancet Oncol
; 22(2): 190-197, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33450184
6.
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer.
Ann Oncol
; 32(3): 395-403, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33276076
7.
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.
Ann Oncol
; 31(6): 798-806, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32209338
8.
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Ann Oncol
; 31(10): 1397-1404, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32634610
9.
Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl JM, and Ay C.
Ann Oncol
; 35(3): 328-329, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38029840
10.
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
Ann Oncol
; 30(7): 1104-1113, 2019 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30977778
11.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.
Ann Oncol
; 30(1): 34-43, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30475943
12.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.
Ann Oncol
; 30(1): 19-33, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30475956
13.
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.
Ann Oncol
; 29(suppl_1): i10-i19, 2018 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29462254
14.
Radiotherapy for the treatment of malignant pleural mesothelioma.
Lancet Oncol
; 18(9): e532-e542, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28884702
15.
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
Ann Oncol
; 28(6): 1250-1259, 2017 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28460066
16.
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
Lancet Oncol
; 17(5): 642-50, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27080216
17.
Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes on outcomes in lung stereotactic body radiotherapy.
Curr Oncol
; 23(4): e362-8, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-27536185
18.
Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status.
Cancer
; 121(4): 545-55, 2015 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25336438
19.
Radiotherapy in the era of immunotherapy: teaching an old dog new tricks.
Eur Respir J
; 56(1)2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32732301
20.
Immediate Versus Deferred Systemic Therapy in Patients With Mesothelioma.
Clin Lung Cancer
; 2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38825405